Crossmark

PDGFβ receptor-targeted delivery of truncated transforming growth factor β receptor type II for improving the in vitro and in vivo anti-renal fibrosis activity via strong inactivation of TGF-β1/Smad signaling pathway

Crossref DOI link: https://doi.org/10.1007/s00210-023-02594-3

Published Online: 2023-07-04

Published Print: 2024-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wang, Bing

Wang, Xiaohua

Dong, Yixin

Liu, Xiaohui

Xu, Liming

Liu, Yong

Wu, Yan

Wang, Chuntao

Liu, Haifeng
Funding

Funding for this research was provided by:

National Natural Sciences Foundation of China (81700544, 81500471)

Heilongjiang Provincial Natural Sciences Foundation of China (LH2022H098)

Heilongjiang Provincial Pharmaceutical and Healthcare Project (20220202040669)

Mudanjiang Applied Technology Research and Development Project (HT2022JG128)

the Doctoral Scientific Research Projects of Mudanjiang Medical University (2021-MYBSKY-061)
License Information

Text and Data Mining valid from 2023-07-04

Version of Record valid from 2023-07-04
More Information

Article History

Received: 11 March 2023

Accepted: 20 June 2023

First Online: 4 July 2023

Declarations

:

: The authors declare no competing interests.

: All experimental protocols in this study were approved by the Mudanjiang Medical University Animal Care and Veterinary Services Committee. The investigations conform to the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health.

: Not applicable.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below